Corbus Pharmaceuticals Holdings Inc (CRBP) USD0.0001
Sell:$7.86Buy:$8.50
$0.27
(3.23%)
- This stock can be held in a
Stocks and Shares ISA$0.27
(3.23%)$0.27
(3.23%)Company Information
About this company
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Key people
Key facts
- EPICCRBP
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS21833P3010
- Market cap$90.40m
- Employees28
- Shares in issue12.23m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.